+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 110 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 5712518
Description Jump to:

Autologous Cell Therapy Market Growth & Trends

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2025 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights

  • The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.
  • The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.
  • The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.
  • Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapeutic Area
1.2.2. Therapy Type
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of chronic and degenerative diseases
3.2.1.2. Reduced risk of autologous cell therapy rejection
3.2.1.3. Growing demand for personalized medicine
3.2.1.4. Increasing investments in research & development
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of therapy and limited affordability
3.2.2.2. Stringent regulatory requirements and long approval timelines
3.3. Autologous Cell Therapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. Pipeline Analysis
3.3.4. COVID-19 Impact Analysis
Chapter 4. Therapy Type Business Analysis
4.1. Global Autologous Cell Therapy Market: Therapy Type Segment Dashboard
4.2. Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
4.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapy Type (USD Million)
4.4. Stem Cell Therapies
4.4.1. Stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. BM, Blood, & Umbilical Cord-derived Stem Cells
4.4.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Adipose-Derived Cells
4.4.3.1. Adipose-Derived Cells market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Non-stem Cell Therapies
4.5.1. Non-stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. T-Cell Therapies
4.5.2.1. T-Cell Therapies market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.2. CAR T Cell Therapy
4.5.2.2.1. CAR T cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.3. T Cell Receptor (TCR)-based
4.5.2.3.1. T Cell Receptor (TCR)-based market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Others
4.5.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Therapeutic Area Business Analysis
5.1. Global Autologous Cell Therapy Market: Therapeutic Area Dashboard
5.2. Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
5.4. Oncology
5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Cardiovascular Diseases
5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Musculoskeletal Disorders
5.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Dermatology
5.7.1. Dermatology market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Others
5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
5.8.2. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework
6.3.1.3. Competitive scenario
6.3.1.4. Target disease prevalence
6.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework
6.3.2.3. Competitive scenario
6.3.2.4. Target disease prevalence
6.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework
6.4.1.3. Competitive scenario
6.4.1.4. Target disease prevalence
6.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework
6.4.2.3. Competitive scenario
6.4.2.4. Target disease prevalence
6.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Switzerland
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework
6.4.3.3. Competitive scenario
6.4.3.4. Target disease prevalence
6.4.3.5. Switzerland market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. Target disease prevalence
6.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Target disease prevalence
6.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Target disease prevalence
6.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. South Korea
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework
6.5.4.3. Competitive scenario
6.5.4.4. Target disease prevalence
6.5.4.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Rest of the World
6.6.1. Rest of the world market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Key Company Position Analysis, 2024
7.3. Company Profiles/Listing
7.3.1. Bluebird bio, Inc.
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Product benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Novartis AG.
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Holostem S.R.L
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Pharmicell Co. Inc
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Gilead Sciences, Inc. (Kite)
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Bristol Myers Squibb Company
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Johnson & Johnson (Janssen Global Services, LLC.)
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. JW Therapeutics
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Vertex Pharamaceuticals Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Autolus therapeutics
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
List of Tables
Table 1 List Of Secondary Sources
Table 2 Global Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 3 Global Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 4 Global Autologous Cell Therapy Market By Region, 2018 - 2030 (USD Million)
Table 5 North America Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
Table 6 North America Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 7 North America Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 8 U.S. Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 9 U.S. Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 10 Canada Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 11 Canada Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 12 Europe Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
Table 13 Europe Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 14 Europe Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 15 Germany Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 16 Germany Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 17 UK Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 18 UK Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 19 Switzerland Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 20 Switzerland Autologous Cell Therapy MarketBy Therapeutic Area, 2018 - 2030 (USD Million)
Table 21 Asia Pacific Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
Table 22 Asia Pacific Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 24 China Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 25 China Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 26 Japan Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 27 Japan Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 28 India Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 29 India Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 30 South Korea Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 31 South Korea Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
Table 32 Rest Of The World Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
Table 33 Rest Of The World Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Autologous Cell Therapy Market, Market Segmentation
Fig. 7 Market Driver Analysis (Current & Future Impact)
Fig. 8 Market Restraint Analysis (Current & Future Impact)
Fig. 9 PESTEL Analysis
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Global Autologous Cell Therapy Market: Therapy Type Key Takeaways
Fig. 12 Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
Fig. 13 Global Autologous Cell Therapy Market For Autologous Stem-Cell Therapies, 2018 - 2030 (USD Million)
Fig. 14 Global Autologous Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cell Therapies, 2018 - 2030 (USD Million)
Fig. 15 Global Autologous Cell Therapy Market For Adipose Derived Cells, 2018 - 2030 (USD Million)
Fig. 16 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
Fig. 17 Global Autologous Cell Therapy Market For Autologous Non-Stem Cell Therapies, 2018 - 2030 (USD Million)
Fig. 18 Global Autologous Cell Therapy Market For T-Cell Therapies, 2018 - 2030 (USD Million)
Fig. 19 Global Autologous Cell Therapy Market For CAR T Cell Therapy, 2018 - 2030 (USD Million)
Fig. 20 Global Autologous Cell Therapy Market For T Cell Receptor (TCR)-Based, 2018 - 2030 (USD Million)
Fig. 21 Global Autologous Cell Therapy Market For Other Autologous Non Stem-Cell Therapies, 2018 - 2030 (USD Million)
Fig. 22 Global Autologous Cell Therapy Market: Therapeutic Area Key Takeaways
Fig. 23 Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
Fig. 24 Global Autologous Cell Therapy Market For Oncology, 2018 - 2030 (USD Million)
Fig. 25 Global Autologous Cell Therapy Market For Cardiovascular Disease (CVD), 2018 - 2030 (USD Million)
Fig. 26 Global Autologous Cell Therapy Market For Musculoskeletal Disorders, 2018 - 2030 (USD Million)
Fig. 27 Global Autologous Cell Therapy Market For Dermatology, 2018 - 2030 (USD Million)
Fig. 28 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
Fig. 29 Regional Outlook, 2024 & 2030
Fig. 30 North America Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 31 U.S.Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 32 Canada Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 33 Europe Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 34 Germany Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 35 UK Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 36 Switzerland Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 37 Asia Pacific Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 38 Japan Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 39 China Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 40 India Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 41 South Korea Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
Fig. 42 Rest Of The World Autologous Cell Therapy Market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Bluebird bio, Inc.
  • Novartis
  • Gilead Sciences, Inc. (Kite)
  • Bristol-Myers Squibb Company
  • Pharmicell Co., Ltd.
  • Johnson & Johnson (Janssen Global Services, LLC.)
  • JW Therapeutics
  • Holostem S.r.l.
  • Vertex Pharmaceuticals, Inc.
  • Autolus therapeutics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages110
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.41 billion
Forecasted Market Value ( USD ) by 2030 $ 18.23 billion
Compound Annual Growth Rate22.0%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Cell Therapy - Global Strategic Business Report - Product Image

Cell Therapy - Global Strategic Business Report

  • Report
  • 263 Pages
  • Global
From
Autologous Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Autologous Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 190 Pages
  • Global
From
Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032 - Product Image

Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032

  • Report
  • 139 Pages
  • Global
From
Cell Therapy Market by Cell Type, Therapy Type, Application, End-User - Global Forecast 2025-2030 - Product Image

Cell Therapy Market by Cell Type, Therapy Type, Application, End-User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From

About the Autologous Cell Therapy Market

Autologous cell therapy is a type of regenerative medicine that uses a patient's own cells to treat a variety of diseases and conditions. It is a form of personalized medicine that is based on the patient's own genetic makeup. Autologous cell therapy is used to treat a variety of conditions, including cancer, autoimmune diseases, and degenerative diseases. Genomics plays an important role in autologous cell therapy, as it allows for the identification of the patient's own cells and the selection of the most appropriate cells for the therapy. Genomics also helps to identify the best treatment strategy for the patient, as well as to monitor the progress of the therapy. Some companies in the autologous cell therapy market include Celgene, Novartis, and Kite Pharma. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.